Confident decision-making starts with identification of the true low-risk group of patients.

Accurate assessment of risk can help patients with low-risk disease that may safely forgo chemotherapy. EndoPredict integrates gene expression with clinicopathological features to identify a large population of true low-risk patients.

EndoPredict was independently validated to produce robust 10-year prognostic results

EndoPredict was developed using consistent criteria for patients during training and independent validation studies - ER+, HER2− patients, both node-negative (N0) and node-positive (N+). All patients received only 5 years of endocrine therapy.

EndoPredict identifies a consistent risk of recurrence in N0 and N+ patients

Filipits et al reported the independent validation of the EndoPredict 12-gene molecular score (EP score) and comprehensive EPclin Risk Score using data from two phase 3 studies, ABCSG-6 and ABCSG-8. Women in these studies received 5 years of endocrine therapy alone. Those in ABCSG-6 received either 5 years of tamoxifen or 2 years of tamoxifen and aminoglutethimide, followed by 3 years of tamoxifen. Those in ABCSG-8 received 5 years tamoxifen or 2 years tamoxifen followed by 3 years of anastrozole.

EndoPredict improves prediction of distant metastases compared to standard assessments

EndoPredict improves prognostic accuracy in comparison to Ki-67

Dubsky P et al 2012 Kaplan-Meier analysis for distant metastasis-free survival of EPclin risk assessment on 1702 ER+, HER2− samples from ABCSG-6 and ABCSG-8 previously identified by Ki-67 molecular subtype as low-risk (luminal A molecular subtype, Ki-67 levels<14%) or high-risk (luminal B molecular subtype, Ki-67 levels ≥14%).

EndoPredict provides improved accuracy in comparison to tumor grade

Dubsky P et al 2012 Kaplan-Meier analysis for distant metastasis-free survival of EPclin risk assessment on 1702 ER+, HER2− samples from ABCSG-6 and ABCSG-8 previously identified by tumor grade 1, 2, or 3.